PROLEASE HGH IN CHILDREN WITH GROWTH FAILURE DUE TO GROWTH HORMONE DEFICIENCY

这项研究是一种新的长效制剂的短期试验 生长激素(HGH)评价其安全性和有效性。治疗的方法 生长激素缺乏症自20世纪60年代末以来，S最初与 身体hGH，然后，随后，与重组hGH，没有 改变了荷尔蒙的给药方法。孩子们 经常注射hGH治疗。最初，这是三个 每周肌肉注射次数，目前的标准治疗是每天 皮下注射hGH。目前正在测试的药物是一种 商业生长激素目前合成了一种聚丙烯酰胺物质 用作一种可溶解的缝合材料，理论上提供一种缓慢的 释放长效hGH。这项研究的目的是评估可能的方面 疗效和短期疗效。未来的计划包括长期研究 来评估这种药物的疗效。

This study is a short-term trial of a new formulation of a long acting growth hormone (hGH) to evaluate its safety and efficacy. The treatment of growth hormone deficiency (GHD) since the late 1960's initially with cadaveric hGH and then, subsequently, with recombinant hGH, has not changed in terms of method of administration of the hormone. The children were treated with frequent injections of hGH. Initially, this was three times per week intramuscularly and present standard treatment is daily subcutaeous injections of hGH. The present drug to be tested is a commercial growth hormone combined into a polyacrimide substance presently used as a dissolvable suture material to provide, theoretically, a slow release long acting hGH. This study is intended to evaluate possible side effects and short term efficacy. Future plans include a long term study of this drug to evaluate efficacy.